Peripheral Inflammatory Biomarkers in First-Episode, Drug-Naïve Major Depressive Disorder: A Systematic Review
Authors:
- Esteban Zavaleta-MonestelEZEsteban Zavaleta-Monestel
- Luis Guillermo Herrera-JiménezLHLuis Guillermo Herrera-Jiménez
- José Miguel Chaverri-FernándezJosé Miguel Chaverri-Fernández
- Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
- Jeaustin Mora-JiménezJMJeaustin Mora-Jiménez
- Ricardo Millán-GonzálezRMRicardo Millán-González
Open Access
- 22 June 2026
- journal article
- review article
- Published by MDPI AG in Psychiatry International
- Vol. 7 (3) , 140
Abstract
Major depressive disorder (MDD) is clinically heterogeneous, and peripheral inflammatory biomarkers may help clarify early biological mechanisms before illness chronicity or pharmacologic treatment confound interpretation. This systematic review synthesized evidence on peripheral inflammatory biomarkers in first-episode, drug-naïve major depressive disorder (FEDN-MDD) compared with healthy controls and examined associations with clinical severity. Following PRISMA 2020, searches of PubMed/MEDLINE, Embase, PsycINFO, and Scopus from inception to 19 March 2026 identified 313 records; after screening, 16 publications were included in qualitative synthesis. Studies varied in age group, biological matrix, assay platform, and statistical reporting, precluding meta-analysis. The most frequently assessed biomarkers were IL-1β, TNF-α, IL-6, and CRP/hs-CRP. IL-6 showed the clearest recurrent tendency toward elevation in FEDN-MDD, whereas CRP/hs-CRP findings were partially positive but methodologically limited. TNF-α and IL-1β findings were mixed, and clinical correlations with depressive severity were sparse and inconsistent. Overall, the evidence supports heterogeneous early immune dysregulation in a subset of patients with FEDN-MDD rather than a single reproducible inflammatory signature. Peripheral inflammatory biomarkers should currently be considered research tools for biological stratification and mechanistic hypothesis generation, pending larger standardized longitudinal studies.Keywords
All Related Versions
This publication has 58 references indexed in Scilit:
- Multivariate Brain-Blood Signatures in Early-Stage Depression and PsychosisJAMA Psychiatry, 2026
- Inflammation, metabolic dysregulation, and depression profiles related to anhedonia and atypical, energy-related symptomsBrain, Behavior, and Immunity, 2025
- Current Position and Future Direction of Inflammation in Neuropsychiatric DisordersJAMA Psychiatry, 2025
- Should Inflammation Be a Specifier for Major Depression in the DSM-6?JAMA Psychiatry, 2025
- Dissecting depression symptoms: Multi-omics clustering uncovers immune-related subgroups and cell-type specific dysregulationBrain, Behavior, and Immunity, 2024
- Exploring the correlation between childhood trauma experiences, inflammation, and brain activity in first-episode, drug-naive major depressive disorderEuropean Archives of Psychiatry and Clinical Neuroscience, 2024
- Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive SymptomsJAMA Psychiatry, 2021
- Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controlsBrain, Behavior, and Immunity, 2020
- Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorderBrain, Behavior, and Immunity, 2015
- Association of Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in Young Adult LifeJAMA Psychiatry, 2014